201 related articles for article (PubMed ID: 15930353)
1. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Strong TV; Bucy RP; Allen KO; Carlisle RR; Moore SE; Lobuglio AF; Conry RM
Hum Gene Ther; 2005 Jan; 16(1):91-100. PubMed ID: 15703492
[TBL] [Abstract][Full Text] [Related]
3. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.
Khorana AA; Rosenblatt JD; Sahasrabudhe DM; Evans T; Ladrigan M; Marquis D; Rosell K; Whiteside T; Phillippe S; Acres B; Slos P; Squiban P; Ross M; Kendra K
Cancer Gene Ther; 2003 Apr; 10(4):251-9. PubMed ID: 12679797
[TBL] [Abstract][Full Text] [Related]
5. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.
Nemunaitis J; Fong T; Robbins JM; Edelman G; Edwards W; Paulson RS; Bruce J; Ognoskie N; Wynne D; Pike M; Kowal K; Merritt J; Ando D
Cancer Gene Ther; 1999; 6(4):322-30. PubMed ID: 10419050
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
[TBL] [Abstract][Full Text] [Related]
8. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
10. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
Cunningham CC; Chada S; Merritt JA; Tong A; Senzer N; Zhang Y; Mhashilkar A; Parker K; Vukelja S; Richards D; Hood J; Coffee K; Nemunaitis J
Mol Ther; 2005 Jan; 11(1):149-59. PubMed ID: 15585416
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
Mastrangelo MJ; Maguire HC; Eisenlohr LC; Laughlin CE; Monken CE; McCue PA; Kovatich AJ; Lattime EC
Cancer Gene Ther; 1999; 6(5):409-22. PubMed ID: 10505851
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
von Mehren M; Arlen P; Tsang KY; Rogatko A; Meropol N; Cooper HS; Davey M; McLaughlin S; Schlom J; Weiner LM
Clin Cancer Res; 2000 Jun; 6(6):2219-28. PubMed ID: 10873071
[TBL] [Abstract][Full Text] [Related]
13. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors.
Addison CL; Bramson JL; Hitt MM; Muller WJ; Gauldie J; Graham FL
Gene Ther; 1998 Oct; 5(10):1400-9. PubMed ID: 9930346
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions.
Rini BI; Selk LM; Vogelzang NJ
Clin Cancer Res; 1999 Oct; 5(10):2766-72. PubMed ID: 10537340
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial.
Mahvi DM; Henry MB; Albertini MR; Weber S; Meredith K; Schalch H; Rakhmilevich A; Hank J; Sondel P
Cancer Gene Ther; 2007 Aug; 14(8):717-23. PubMed ID: 17557109
[TBL] [Abstract][Full Text] [Related]
17. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.
Trakatelli M; Toungouz M; Lambermont M; Heenen M; Velu T; Bruyns C
Cancer Gene Ther; 2005 Jun; 12(6):552-9. PubMed ID: 15665821
[TBL] [Abstract][Full Text] [Related]
18. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
[TBL] [Abstract][Full Text] [Related]
19. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.
Mukherjee S; Haenel T; Himbeck R; Scott B; Ramshaw I; Lake RA; Harnett G; Phillips P; Morey S; Smith D; Davidson JA; Musk AW; Robinson B
Cancer Gene Ther; 2000 May; 7(5):663-70. PubMed ID: 10830713
[TBL] [Abstract][Full Text] [Related]
20. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
